Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
San Diego, CA, November 19, 2004 The Washington Neuropsychological Institute today announced that preliminary data suggested that ADDERALL XR significantly improved simulated driving performance in young adults aged 19 to 25 years with attention-deficit/hyperactivity disorder (ADHD) for up to 12 hours after taking the medication, as compared with placebo. In addition, ADDERALL XR significantly...Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA
Washington, DC, October 20, 2004 Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced today that ADDERALL XR (an extended release, mixed salts amphetamine product) is effective and generally well-tolerated for adolescents with attention-deficit/hyperactivity disorder (ADHD). The short- and long-term study results of the multicenter Phase 3 study were presented toda...FDA approves Adderall XR (R) to treat ADHD in adults
Philadelphia, Pa. Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the US Food and Drug Administration (FDA) has approved ADDERALL XR® (mixed salts of a single-entity amphetamine) as a once-daily treatment for adults with Attention Deficit Hyperactivity Disorder (ADHD). Since 2001, ADDERALL XR has been approved in the U.S. for the treatment of ADHD in...Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
New York, NY, May 6, 2004 Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that adults with attention-deficit/hyperactivity disorder (ADHD) experienced significant ADHD symptom control when treated with once-daily ADDERALL XR (a mixed salts amphetamine product). The 18-month interim analysis of a two-year Phase III trial led by Harvard investigators was discuss...Shire receives approvable letter for adult ADDERALL XR(R) from FDA
Rockville, Maryland US October 20, 2003 Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for ADDERALL XR (R) once daily treatment for adult Attention Deficit Hyperactivity Disorder (ADHD).... ...The Supplemental New Drug Application (sNDA), which was submitted to the FDA on...Children achieve sustained ADHD symptom improvement with long-term, once-daily use of Adderall XR
Children achieve sustained ADHD symptom improvement ...with long-term, once-daily use of a mixed salts amphetamine product ... ......San Francisco, CA, May 21, 2003 Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced results of a long-term clinical trial that showed significant improvements in symptom control and quality of life in children with attention-deficit/.... BUFFALO, N.Y. -- The first trial of comparable doses of Ritalin, the.standard treatment for children with attention deficit/hyperactivity disorder.(ADHD), and Adderall, another drug used to treat ADHD, has shown that Adderall.lasts longer than Ritalin and is at least as effective.. . In addition, staff supervising and observing the children during the.trial, who were blinded to t...